Search Videos and More
Telehealth Can Significantly Reduce Greenhouse Gas Emissions Associated with Cancer Care, Study Finds
Telemedicine visits for cancer care may not only be more convenient and easier to schedule than in-person appointments, they're also better for the planet, new research by Dana-Farber Cancer Institute scientists shows.AACR 2024 Highlights
Review presentations and information shared by Dana-Farber physician-scientists at the 2024 American Association of Cancer Research (AACR) Annual Meeting held April 5-10, San Diego, CA.Science Behind Targeted Drug for Pediatric Brain Cancer Has Dana-Farber Roots
Two separate research teams had discovered a genetic driver for the most common of childhood brain tumors called pediatric low-grade glioma.Dana-Farber Researchers Discover New Target for Potential Leukemia Therapy
A team of Dana-Farber Cancer Institute investigators discovered that a subset of myeloid and lymphoid leukemias depend on a molecular complex called PI3Kgamma for survival.Most Young Women Treated For Breast Cancer Can Have Children, Study Shows
In a study of nearly 200 young women who have survived breast cancer, most of those who tried to conceive were able to become pregnant and give birth.2024 American Society of Clinical Oncology (ASCO)
New $15 Million Grant to Dana-Farber Scientists Supports Research into Innovative Approaches to Endometrial Cancer Treatment
Physician-scientists at Dana-Farber Cancer Institute have received a five-year, $15 million Program Project Grant from the National Cancer Institute (NCI) for research in endometrial cancer, which arises in the inner lining of the uterus and strikes more than 68,000 women a year in the U.S.Dana-Farber Research Publication 05.01.2024
This twice-monthly newsletter highlights the research endeavors at Dana-Farber Cancer Institute, noting recently published papers available from PubMed where Dana-Farber faculty are listed as first or senior authors.Unraveling the Menin Mystery to Halt Cancer Growth
The story of research in menin and its relation to cancer — from early efforts to understand how the cell makes use of menin, to explorations of the cell machinery operated by menin, to the development and testing of agents that inhibit menin, to work on preventing resistance to such agents — weaves through Dana-Farber at every step.Dana-Farber Researchers Explore AI's Potential Roles in Predicting and Diagnosing Cancer
In 2022 and 2023, you couldn't go a day without hearing about artificial intelligence (AI). Generative AI tools such as chatbots and art generators had become a central topic in everyday conversations. But AI in cancer has deeper roots. Twenty-five years before ChatGPT burst onto the scene, computers started playing a larger role in cancer diagnostics. In 1997, mammograms weren't even digital yet, but computers had started analyzing them. The tools, called expert systems, used hard-coded logic to read digital images of X-ray-based mammograms to look for signs of cancer.Ancient DNA Reveals Origin of Racial/Ethnic Disparity in a Childhood Cancer
There are 40% more Hispanic/Latino kids diagnosed with acute lymphoblastic leukemia (ALL) than white non-Hispanic/Latino children; actually, Hispanic/Latino individuals have the highest risk of ALL in the United States. However, the basis for this difference is not well understood. Researchers recently identified a genetic variant that accounts for the increased risk of B-cell ALL in Hispanic/Latino children, and using ancient DNA, they traced the mutation all the way back to the first migrants who entered the Americas ~13,000 years ago.Breast Cancer Trial Aims to Improve Treatment for Men
Over the past 30 years, outcomes have improved dramatically for women with breast cancer. There are many new treatments, including hormone therapies and CDK4/6 inhibitors. In contrast, there has been no improvement in the outcomes for men with breast cancer. And current guidelines don’t support the use of newer therapies in men. Male breast cancer accounts for just 1% of all cases of breast cancer. Advancing care for a rare group requires a focused effort, so Jose Pablo Leone, MD, has invested energy into designing and leading a clinical trial for men with breast cancer.